114 related articles for article (PubMed ID: 38411494)
1. Sorafenib and tetrakis (4-carboxyphenyl) porphyrin assembled nanoparticles for synergistic targeted chemotherapy and sonodynamic therapy of hepatocellular carcinoma.
Chen Y; Tan Q; Tang Y; Pang E; Peng R; Lan M; Bai D
Biomater Sci; 2024 Mar; 12(7):1864-1870. PubMed ID: 38411494
[TBL] [Abstract][Full Text] [Related]
2. Bimodal Treatment of Hepatocellular Carcinoma by Targeted Minimally Interventional Photodynamic/Chemotherapy Using Glyco-Covalent-Organic Frameworks-Guided Porphyrin/Sorafenib.
Hu J; Hu J; Wu W; Qin Y; Fu J; Liu C; Seeberger PH; Yin J
Acta Biomater; 2022 Aug; 148():206-217. PubMed ID: 35697198
[TBL] [Abstract][Full Text] [Related]
3. Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid.
Yurdacan B; Egeli U; Guney Eskiler G; Eryilmaz IE; Cecener G; Tunca B
J Pharm Pharmacol; 2019 Jul; 71(7):1119-1132. PubMed ID: 31025377
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression.
Wu MH; Chiu YF; Wu WJ; Wu PL; Lin CY; Lin CL; Hsieh YH; Liu CJ
Environ Toxicol; 2018 Dec; 33(12):1237-1244. PubMed ID: 30187994
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib-Encapsulated Liposomes to Activate Hypoxia-Sensitive Tirapazamine for Synergistic Chemotherapy of Hepatocellular Carcinoma.
Zhao J; Dai W; Zhan L; Lei L; Jin Q; Wang J; Tang Z
ACS Appl Mater Interfaces; 2024 Mar; 16(9):11289-11304. PubMed ID: 38393963
[TBL] [Abstract][Full Text] [Related]
7. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis.
Al-Noshokaty TM; Mesbah NM; Abo-Elmatty DM; Abulsoud AI; Abdel-Hamed AR
Life Sci; 2022 Aug; 303():120675. PubMed ID: 35640776
[TBL] [Abstract][Full Text] [Related]
8. A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells.
Younis MA; Khalil IA; Abd Elwakil MM; Harashima H
Mol Pharm; 2019 Sep; 16(9):4031-4044. PubMed ID: 31403802
[TBL] [Abstract][Full Text] [Related]
9. N-acetyl-galactosamine modified metal-organic frameworks to inhibit the growth and pulmonary metastasis of liver cancer stem cells through targeted chemotherapy and starvation therapy.
Hu J; Hu J; Wu W; Qin Y; Fu J; Zhou J; Liu C; Yin J
Acta Biomater; 2022 Oct; 151():588-599. PubMed ID: 36002126
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment.
Zan Y; Dai Z; Liang L; Deng Y; Dong L
Drug Deliv; 2019 Dec; 26(1):1080-1091. PubMed ID: 31735093
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma.
Ye J; Zhang R; Chai W; Du X
Drug Deliv; 2018 Nov; 25(1):2007-2014. PubMed ID: 30799656
[TBL] [Abstract][Full Text] [Related]
12. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
[TBL] [Abstract][Full Text] [Related]
13. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects.
Romito I; Porru M; Braghini MR; Pompili L; Panera N; Crudele A; Gnani D; De Stefanis C; Scarsella M; Pomella S; Levi Mortera S; de Billy E; Conti AL; Marzano V; Putignani L; Vinciguerra M; Balsano C; Pastore A; Rota R; Tartaglia M; Leonetti C; Alisi A
J Exp Clin Cancer Res; 2021 Nov; 40(1):364. PubMed ID: 34784956
[TBL] [Abstract][Full Text] [Related]
14. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Liu X; Zhu X; Qi X; Meng X; Xu K
Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
[TBL] [Abstract][Full Text] [Related]
15. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
Zhang J; Hu J; Chan HF; Skibba M; Liang G; Chen M
Nanomedicine; 2016 Jul; 12(5):1303-11. PubMed ID: 26964482
[TBL] [Abstract][Full Text] [Related]
16. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
17. Bismuth-Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma.
Zhang GC; Liu J; Yu XN; Deng Y; Sun Y; Liu TT; Dong L; Zhu CF; Shen XZ; Zhu JM; Weng SQ; Li Y
Adv Healthc Mater; 2020 Nov; 9(21):e2000650. PubMed ID: 33000919
[TBL] [Abstract][Full Text] [Related]
18. Integrated platform of oxygen self-enriched nanovesicles: SP94 peptide-directed chemo/sonodynamic therapy for liver cancer.
Zhang W; Han B; Gao C; Liu X; Peng Y; Gong C; Hu D; Wang N; Tang S; Zhang B; Zhao M; Peng H
Eur J Pharm Biopharm; 2022 Oct; 179():206-220. PubMed ID: 36150614
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
Wang Y; Yu H; Zhang D; Wang G; Song W; Liu Y; Ma S; Tang Z; Liu Z; Sakurai K; Chen X
Acta Biomater; 2019 Jul; 92():229-240. PubMed ID: 31100462
[TBL] [Abstract][Full Text] [Related]
20. Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment.
Bieniek A; Wiśniewski M; Czarnecka J; Wierzbicki J; Ziętek M; Nowacki M; Grzanka D; Kloskowski T; Roszek K
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
